Revive Therapeutics Ltd. (RVVTF)
| Previous Close | 0.4100 |
| Open | 0.3820 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.3820 - 0.4099 |
| 52 Week Range | 0.2370 - 0.7200 |
| Volume | |
| Avg. Volume | 700,917 |
| Market Cap | 123.463M |
| Beta (5Y Monthly) | 0.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0500 |
| Earnings Date | Feb. 28, 2022 - Mar. 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Baystreet
Stocks in play: Revive Therapeutics Ltd.
Announced it has granted 325,000 incentive stock options exercisable into common shares of the Company ...
- GlobeNewswire
UPDATE -- Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial
Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529)Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2)Adding inflammatory markers along with viral load testing to current Phase 3 clinical study for COVID-19 aiming to strengthen Bucillamine’s profile as both an anti-viral and anti-inflammatory agent for infectious diseases TORONTO, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Comp
- GlobeNewswire
Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial
Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529)Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2)Adding inflammatory markers along with viral load testing to current Phase 3 clinical study for COVID-19 aiming to strengthen Bucillamine’s profile as both an anti-viral and anti-inflammatory agent for infectious diseases TORONTO, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Comp
